Tag:
Miragen Therapeutics
Latest Headlines
Latest Headlines
Argos and miRagen add new venture rounds to back R&D efforts
Just a few weeks after giving up on its IPO, Durham, NC-based Argos Therapeutics rounded up a $25 million D round to pay for a late-stage study of a renal cell carcinoma therapy slated to begin later this year.
Corporate venture arms step in where traditional players fear to tread
Big Pharma's corporate venture arms have been flexing their financial muscles this year. Coming into the venture game with a patient attitude and a big interest in earlier-stage R&D enterprises,
UPDATED: MiRagen lands $352M microRNA development pact with Servier
Boulder, CO-based miRagen has racked up its first big collaboration, inking a development pact with France's Servier for two of its top preclinical programs as well as a third, as yet unidentified,
Kythera garners $40M in third venture round
LA-based Kythera Biopharmaceuticals is looking for a key assist in Japan from a new investor. JAFCO has led a $40 million Series C for the biotech developer of "aesthetic" therapies. BBT Capital
